<DOC>
	<DOCNO>NCT01834586</DOCNO>
	<brief_summary>The purpose study see apply anesthetic topical adhesive , Synera® , reduce injection pain . Relieving injection site pain may improve tolerability Multiple Sclerosis medication . Study Hypothesis : Pre-medication Synera significant effect pain rating measure visual analog scale Local injection site reaction scale .</brief_summary>
	<brief_title>Anesthetic Topical Adhesive ( Synera™ ) Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications</brief_title>
	<detailed_description>Open-label prospective study Synera reduce injection pain 30 patient relapse form Multiple Sclerosis take interferon beta glatiramer acetate . The duration 3-6 week ( 1-2 week baseline observation follow 2-4 week on-drug observation ) , depend Multiple Sclerosis drug product study . The study include down-titration 60 30 minute application ass difference response . We define one primary outcome measure , '' pain upon injection '' visual analog scale ( VAS ) . Secondary measure include 24-hour rating pain VAS 24-hour local injection site reaction ( LISR ) scale score .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Anesthetics</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<mesh_term>Anesthetics , Local</mesh_term>
	<criteria>Confirmed diagnosis Multiple Sclerosis base McDonald Poser criterion ( subtype restriction ) Aged &gt; 18 Regular use one follow Multiple Sclerosis medication treatment : interferon beta subcutaneous ( 15 subject , Betaseron , Extavia Rebif ) , glatiramer acetate subcutaneous ( 15 subject , Copaxone ) . No change disease modify therapy 60 day . Mean score ≥1.0 Local Injection Site Reaction scale Mean Pain Upon Injection score ≥4.0 baseline period . At least 4 valid diary entry screen period . No Multiple Sclerosis exacerbation 60 day prior screen . Written inform consent Females breastfeeding , pregnant potential become pregnant course study ( fertile unwilling/unable use effective contraceptive measure ) . Cognitive deficit would interfere subject 's ability give inform consent perform study test . Concurrent application topical medication treat injection site reaction screen final visit . History allergy lidocaine , tetracaine PABA ( paraamino benzoic acid ) containing product . Patients receive class 1 antiarrhythmic agent ( i.e . tocainide , mexiletine ) Any serious and/or unstable medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>